Please login to the form below

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis wins FDA approval for relapsing MS drug Kesimpta

Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).

Latest news

Novartis builds its case for novel MS treatment ofatumumab

The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).
J&J aims for US approval of MS drug ponesimod

If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only
Cosentyx, Entresto drive topline growth for Novartis in Q4

Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and
Novartis gets EU approval for multiple sclerosis therapy Mayzent

Offers subgroup of patients an important new treatment option. The European Commission has approved Novartis’ Mayzent (siponimod) for use in adults with active secondary progressive multiple sclerosis (SPMS).
Biogen under fire over $88,000 Vumerity annual price

As well as facing pricing pressures and legal battles, Biogen will also be challenged by newly launched or anticipated rival therapies including Novartis’ Mayzent (siponimod) and Roche’s Ocrevus (ocelizumab) which

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow
Tackling a formidable foe

Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...